ecancermedicalscience

Conference Report

Orlando Magic: report from the 57th meeting of the American Society of Haematology, 5–7 December 2015, Orlando, USA

14 Jan 2016
Luca Mazzarella

The 57th American Society of Haematology (ASH) meeting held in Orlando, FL was certainly the year when myeloma management changed for good, with a plethora of newly Food and Drug Administration (FDA)-approved drugs showing impressive outcome improvements and the introduction of new techniques for disease monitoring. Also, chimeric antigen receptor (CAR) T cells continued their triumphal march, consolidating their success in lymphoma and chronic lymphocytic leukaemia (CLL) and venturing into new fields such as again multiple myeloma. Some experimental drugs showed long-awaited results (midostaurin in FLT3-mutated acute myeloid leukaemia (AML)) and some brand new drugs showed promising results in the clinic after extensive preclinical studies, such as those targeting new epigenetic factors (histone methyltransferases) and apoptosis.

Article metrics: 750 views
226
524

Related Articles

Kai Sun, Ryan J Reynolds, Tiffany G Sheu, Jessica A Tomsula, Lara Colton, Lawrence Rice
Ethan A Burns, Amna Ahmed, Anusha Sunkara, Usman Khan, Roozbeh Sharif, Maen Abdelrahim, Michael Reardon, Barry Trachtenberg
Liliana Castro Oliveira, Carlos Fardilha, Manuel Louro, Carlos Pinheiro, Abílio Sousa, Herlander Marques, Paulo Costa
Amit Joshi, Shruti Kate, Vanita Noronha, Vijay Patil, Vaishakhi Trivedi, Supriya Goud, Sucheta More, Sandeep Bhairva, Kumar Prabhash